NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/18/2024
Back to search
Official data from USPTO
CEVEC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CEVEC
ST13
US500000079035160Class
1, 5, 42, 44
Filing
79035160
Registration
3405717
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
60
Latest update
10/18/2024
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
11/03/2006
Registration date
04/01/2008
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/23/2017
Last transaction
08/09/2024
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
51105 Köln, DE
Examiner
KUNG, KAELIE
Law office
L30
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH
Representatives
Dyan M. House Baker & Mckenzie, LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical preparations for scientific purposes and biological products for scientific purposes in the nature of microorganismseukaryotic cell culture linespolypeptidesproteinsnucleic acidsviral vectors and gene expression vectorsexcept for medical and veterinary purposes; chemical and biological preparations other than for medical or veterinary purposesfor use in research and characterization of diseasesdiagnostic preparations for scientific and research use; cultures of microorganisms for scientific purposeseukaryotic cell culture lines for scientific purposes
Class 5
Medicaments for the treatment of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseases; pharmaceutical and veterinary preparations for use in the treatment of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseases; chemical and biological preparations for medical usefor medical diagnosis and analysis; eukaryotic cell culture linesmicroorganismspolypeptidesnucleic acids for medical and medical diagnostic purposes
Class 42
Scientific and industrial research and consulting servicesin particular in the fields of molecular biologybiotechnologygenetics; pharmaceutical research and development; medical research and development of methods of medical therapy; scientific and technological services in the nature of breedingrecoveryoptimizationsynthesis and modification of eukaryotic cell culture linesmicro-organismspolypeptidesnucleic acids for third parties; research services in the fields of medicine and pharmaceuticals; medical and scientific researchconducting clinical trials for third parties
Class 44
Medical and veterinary services; medical servicesbreedingrecoveryoptimizationsynthesis and modification of eukaryotic cell culture linesmicro-organismspolypeptidesnucleic acids for third parties; consulting services in the fields of medicine and pharmaceuticals
Publications
History of USPTO decisions and trademark events.
60 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/09/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
08/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/09/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/09/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/09/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/19/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/21/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
08/21/2023
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
08/21/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/21/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/21/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/21/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/21/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/13/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
07/13/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/13/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/13/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/11/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
06/11/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/11/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/11/2021
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
10/19/2018
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
09/11/2018
INPC
INVALIDATION PROCESSED
09/11/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
08/23/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/17/2018
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
12/23/2017
71AG
REGISTERED-SEC.71 ACCEPTED
12/23/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/09/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/27/2017
ES71
TEAS SECTION 71 RECEIVED
11/15/2017
RNWL
INTERNATIONAL REGISTRATION RENEWED
11/17/2016
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - MAILED
04/11/2014
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
04/11/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/11/2014
715F
REGISTERED - SEC. 71 & SEC. 15 FILED
03/10/2014
ES75
TEAS SECTION 71 & 15 RECEIVED
03/10/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/22/2012
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/17/2008
FIMP
FINAL DISPOSITION PROCESSED
07/17/2008
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/03/2008
R.PR
REGISTERED-PRINCIPAL REGISTER
04/01/2008
PUBO
PUBLISHED FOR OPPOSITION
01/15/2008
NPUB
NOTICE OF PUBLICATION
12/26/2007
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/11/2007
ALIE
ASSIGNED TO LIE
12/10/2007
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/02/2007
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/10/2007
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/10/2007
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/10/2007
RFNT
REFUSAL PROCESSED BY IB
05/03/2007
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/12/2007
RFRR
REFUSAL PROCESSED BY MPU
04/12/2007
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/11/2007
CNRT
NON-FINAL ACTION WRITTEN
04/10/2007
DOCK
ASSIGNED TO EXAMINER
03/30/2007
NWAP
NEW APPLICATION ENTERED
03/30/2007
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/29/2007
Continuous trademark protection
Get notified about every new filing that threatens CEVEC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.